Robert U. Newton, N. Hart, D. Galvão, D. Taaffe, F. Saad
{"title":"运动医学治疗前列腺癌","authors":"Robert U. Newton, N. Hart, D. Galvão, D. Taaffe, F. Saad","doi":"10.1002/tre.884","DOIUrl":null,"url":null,"abstract":"Exercise can reduce the risk of death in men with prostate cancer. Although the effect was demonstrated over 10 years ago, exercise medicine is still not recognised as a critical therapy in cancer management. Nevertheless, the evidence base is building, and an ongoing randomised controlled trial has been designed to assess whether a targeted and highly sophisticated exercise medicine intervention causes a survival advantage in men with metastatic castrate‐resistant prostate cancer.","PeriodicalId":42819,"journal":{"name":"Trends in Urology & Mens Health","volume":"72 6 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Prostate cancer treatment with exercise medicine\",\"authors\":\"Robert U. Newton, N. Hart, D. Galvão, D. Taaffe, F. Saad\",\"doi\":\"10.1002/tre.884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Exercise can reduce the risk of death in men with prostate cancer. Although the effect was demonstrated over 10 years ago, exercise medicine is still not recognised as a critical therapy in cancer management. Nevertheless, the evidence base is building, and an ongoing randomised controlled trial has been designed to assess whether a targeted and highly sophisticated exercise medicine intervention causes a survival advantage in men with metastatic castrate‐resistant prostate cancer.\",\"PeriodicalId\":42819,\"journal\":{\"name\":\"Trends in Urology & Mens Health\",\"volume\":\"72 6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Urology & Mens Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/tre.884\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Urology & Mens Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/tre.884","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Exercise can reduce the risk of death in men with prostate cancer. Although the effect was demonstrated over 10 years ago, exercise medicine is still not recognised as a critical therapy in cancer management. Nevertheless, the evidence base is building, and an ongoing randomised controlled trial has been designed to assess whether a targeted and highly sophisticated exercise medicine intervention causes a survival advantage in men with metastatic castrate‐resistant prostate cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
